Intuitive Surgical Today
Intuitive Surgical
As of 07/17/2026 04:00 PM Eastern
- 52 week interval
- $344.55
▼
$603.88
- The P/E ratio
- 39.57
- Target Value
- $523.46
The company makes the da Vinci surgical system, which has an installed base of more than 11,700 systems as of June 30, 2026.
That was one of the highlights from the company's Q2 2026 earnings report.
In the report, released after the market closed on July 16, the company presented impressive numbers.
-
Revenue for the second quarter of 2026 of $2.89 billion increased by 19%, compared to $2.44 billion in the second quarter of 2025.
-
Second quarter 2026 non-GAAP net income attributable to Intuitive Surgical, Inc. was $1 billion, or $2.80 per diluted share, compared to $800 million, or $2.19 per diluted share, in the second quarter of 2025.
-
The company repurchased 0.9 million shares of its common stock for $380 million in the second quarter of 2026.
Despite the strong report, ISRG fell nearly 10% in after-hours trading. The main reason is that the company did not raise its annual guidance for da Vinci procedures. The company's previous guidance was 13.5% to 15.5%, which would mark its slowest growth in several years.
A Kink in the Company's Vital Flywheel
To be fair, Intuitive Surgical is still posting impressive growth numbers for its da Vinci system. The quarter just ended:
-
Globally da Vinci procedures grew by about 15% year-on-year (YOY).
-
The company has placed plans for 468 da Vinci surgeries, compared to 395 in the second half of 2025.
-
Second quarter 2026 da Vinci surgical system installations include 246 da Vinci 5 systems, compared to 180 in second quarter 2025.
-
The company grew its da Vinci surgical system installed base to 11,710 systems as of June 30, 2026, an increase of 12% YOY.
But it's hard to overstate how important da Vinci was to the growth of Intuitive Surgical. The program is a one-time purchase. But it offers a host of services, tools, and resources that drive revenue and profit.
To be honest, ISRG has been going down since July 14. That's it HCA Healthcare NYSE: HCA it reduced its outlook for the year, which meant fewer surgical procedures and sent all medical equipment stocks tumbling.
That's not what Intuitive Surgical is all about. It just reports slow growth. However, growth is still growth.
Why Intuitive Surgical Stock Still Commands a Premium Rating
Intuitive Surgical MarketRank™ Stock Analysis
- Overall MarketRank™
- 94th Percentile
- Analyst rating
- Buy Medium
- Under/Under
- 51.5% is high
- Short Term Interest Rate
- You are healthy
- Dividend Power
- N/A
- News Experience
- 0.40
- Insider Trading
- Selling Shares
- Proj. Income Growth
- 14.59%
See Full Analysis
At the close of trading on July 16, Intuitive Surgical traded at about 46x forward earnings. That's a premium to the S&P 500, but for new investors in ISRG, it's a discount to previous price-to-earnings (P/E) ratios, which at one point a few years ago were nearly 60x.
However, ISRG is expensive at a time when investors are more sensitive to the value they are getting for the price. Some investors will target companies like Medtronic NYSE: MDT again Boston Scientific NYSE: BSXthey are also in the medical devices sector and trade at a much lower multiple than Intuitive Surgical.
However, those companies have a broad product portfolio. While Intuitive Surgical is laser focused on the DaVinci system. The point is not to compare apples to apples. However, even as a standalone stock, ISRG has always commanded a premium price.
Intuitive Surgical Stock Breaks Below Long-Term Support
The weekly chart shows that ISRG is now trading below its 200-week simple moving average (411.89) for the first time in years. This level served as reliable support throughout the 2023-2025 uptrend. Ahead of the earnings report, shares are down about 32% from last year's high near $590. A post-acquisition decline to around $359 would represent a decisive break below that long-term trend line.
The weekly RSI sits at 35.97, its lowest reading since the 2022 bear market, although it is not yet in the oversold area below 30. That leaves room for further declines before tech buyers intervene. A retracement of the 200-week average would be the first signal that the technical picture is stabilizing.
Why Understandable Surgery Sales May Explode
In an age where high-speed algorithms are programmed to make buy/sell decisions based on raw data, this may be an overcorrection. It is possible that the stock will reverse course in the coming days. Analysts remain bearish on ISRG with a consensus price target of $530.92, which represents about a 50% renewal probability.
That means if the stock continues to decline, as analysts maintain bullish intentions, the opportunity for patient investors becomes even greater. The company may not have an impenetrable trench, but it is well fortified. For investors who have had ISRG on their watch list, the time to buy may be coming.
Before you consider Intuitive Surgical, you'll want to hear this.
MarketBeat tracks Wall Street's top and most effective research analysts and the stocks they recommend to their clients every day. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Intuitive Surgical wasn't on the list.
Although Intuitive Surgical currently has an Average Buy rating among analysts, top analysts believe these five stocks are the best.
View Five Stocks Here
The AI boom goes beyond big tech names. Discover 10 companies that provide memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may come from—and the key risks investors should watch as global AI adoption accelerates.
Get This Free Report
